Stephen Schuster
Chair · University of Pennsylvania Health System
Credentials: · · · · ·
History
- 1987–1988
1984–1987
Research
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
New England Journal of Medicine · 2019 · First of 25 authors · 3,379 citations
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
New England Journal of Medicine · 2015 · 2,937 citations
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
New England Journal of Medicine · 2017 · First of 16 authors · 1,525 citations
91 papers
86 papers · 4 as a fellow
70 papers · 14 as a resident
66 papers
59 papers · 2 as a fellow
48 papers · 4 as a fellow
- DT
48 papers · 5 as a fellow
47 papers
Grants
- 2021–2026
National Cancer Institute · R01
PI · $2.3M · University of Pennsylvania
- 1990–1995
Renal Erythropoietin Gene Expression
National Heart, Lung, and Blood Institute · K08
Contact PI · $357.9K · Thomas Jefferson University
- 1986
Cellular, Origin of Erythropoietin
National Heart, Lung, and Blood Institute · F32
Contact PI · $60K · Thomas Jefferson University
Clinical trials
- 2026–2042
huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
Principal investigator · Recruiting · Phase 1
University of Pennsylvania
- 2026
Retreatment With CTL019/CTL119
Principal investigator · Withdrawn · Phase 1
University of Pennsylvania
- 2021–2028
CAR-T Followed by Bispecific Antibodies
Principal investigator · Active not recruiting · Phase 2
Abramson Cancer Center at Penn Medicine
- 2019–2020
Principal investigator · Withdrawn · Phase 1, Phase 2
Abramson Cancer Center at Penn Medicine